211 related articles for article (PubMed ID: 30132131)
1. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Menter T; Tzankov A
Virchows Arch; 2019 Apr; 474(4):497-509. PubMed ID: 30132131
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
5. Cooperative epigenetic modulation by cancer amplicon genes.
Rui L; Emre NC; Kruhlak MJ; Chung HJ; Steidl C; Slack G; Wright GW; Lenz G; Ngo VN; Shaffer AL; Xu W; Zhao H; Yang Y; Lamy L; Davis RE; Xiao W; Powell J; Maloney D; Thomas CJ; Möller P; Rosenwald A; Ott G; Muller-Hermelink HK; Savage K; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Weisenburger DD; Chan WC; Gascoyne RD; Levens D; Staudt LM
Cancer Cell; 2010 Dec; 18(6):590-605. PubMed ID: 21156283
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
[TBL] [Abstract][Full Text] [Related]
7. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
Meier C; Hoeller S; Bourgau C; Hirschmann P; Schwaller J; Went P; Pileri SA; Reiter A; Dirnhofer S; Tzankov A
Mod Pathol; 2009 Mar; 22(3):476-87. PubMed ID: 19136931
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
11. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
12. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
13. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
[TBL] [Abstract][Full Text] [Related]
14. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Blood; 2005 Mar; 105(6):2535-42. PubMed ID: 15572583
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.
Chong LC; Twa DD; Mottok A; Ben-Neriah S; Woolcock BW; Zhao Y; Savage KJ; Marra MA; Scott DW; Gascoyne RD; Morin RD; Mungall AJ; Steidl C
Blood; 2016 Sep; 128(9):1206-13. PubMed ID: 27268263
[TBL] [Abstract][Full Text] [Related]
16. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
Twa DD; Chan FC; Ben-Neriah S; Woolcock BW; Mottok A; Tan KL; Slack GW; Gunawardana J; Lim RS; McPherson AW; Kridel R; Telenius A; Scott DW; Savage KJ; Shah SP; Gascoyne RD; Steidl C
Blood; 2014 Mar; 123(13):2062-5. PubMed ID: 24497532
[TBL] [Abstract][Full Text] [Related]
17. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
[TBL] [Abstract][Full Text] [Related]
19. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract][Full Text] [Related]
20. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]